Abstract: Heterocyclic compounds and methods of making them and using them.

Abstract: The invention features substituted fused bicyclic compounds, pharmaceutical compositions containing them, and methods of using them to treat or prevent histamine-mediated diseases and conditions.

Abstract: Pharmaceutically useful heterocyclic compounds, compositions containing them, and methods of using them, for example, as histamine H3 receptor mediators.

Abstract: The invention features methods of using pharmaceutically-active 2- or 3-aryl substituted imidazopyridines for the treatment of histamine H3 receptor-mediated disorders.

Abstract: The invention features methods of using pharmaceutically-active 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzthiazoles and derivatives.

Abstract: Substituted aryloxyalkylamines of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.

Abstract: Substituted non-imidazole aryloxypiperidine compounds, compositions containing them, and methods of making and using them to treat or prevent histamine-mediated conditions.

Abstract: The invention features pharmaceutically-active imidazopyridines and derivatives that are substituted with phenyl, methods of making them, and methods of using them.

Abstract: The invention features methods of using pharmaceutically-active 2- or 3-aryl substituted imidazopyridines and derivatives.

Abstract: Compounds within the genus represented by the structural formula I ##STR1## or a pharmaceutically acceptable salt thereof, wherein: T is substituted phenyl or substituted pyridyl; ##STR2## R.sup.4 is methyl or ethyl; and Z is substituted piperidinyl.

Abstract: Compound represented by the structural formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein: a is 0, 1, 2 or3;b, d and e are independently 0, 1 or 2;R is H, C.sub.1-6 alkyl, --OH or C.sub.2 -C.sub.6 hydroxyalkyl;A is an optionally substituted oxime, hydrazone or olefin;X is a bond, --C(O)--, --O--, --NR.sup.6 --, --S(O)e--, --N(R.sup.6)C(O)--, --C(O)N(R.sup.6)-- --OC(O)NR.sup.6 --, --OC(.dbd.S)NR.sup.6 --, --N(R.sup.6)C(.dbd.S)O--, --C(.dbd.NOR.sup.1)--, --S(O).sub.2 N(R.sup.6)--, --N(R.sup.6)S(O).sub.2 --, --N(R.sup.6)C(O)O-- or --OC(O)--;T is H, phthalimidyl, aryl, heterocycloalkyl, heteroaryl, cycloalkyl or bridged cycloalkyl;Q is --SR.sup.6, --N(R.sup.6)(R.sup.7), --OR.sup.6, phenyl, naphthyl or heteroaryl;R.sup.6a, R.sup.7a, R.sup.8a, R.sup.9a, R.sup.6 and R.sup.7 are H, C.sub.1-6 alkyl, C.sub.2 -C.sub.6 hydroxyalkyl, C.sub.1 -C.sub.6 alkoxy-C.sub.1 -C.sub.6 alkyl, phenyl or benzyl; or R.sup.6 and R.sup.7, together with the nitrogen to which they are attached, form a ring;R.sup.

Abstract: Compound represented by the structural formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein: a is 0, 1, 2 or 3;b, d and e are independently 0, 1 or 2;R is H, C.sub.1-6 alkyl, --OH or C.sub.2 -C.sub.6 hydroxyalkyl;A is an optionally substituted oxime, hydrazone or olefin;X is a bond, --C(O)--, --O--, --NR.sup.6 --, --S(O).sub.e --, --N(R.sup.6)C(O)--, --C(O)N(R.sup.6)--OC(O)NR.sup.6 --, --OC(.dbd.S)NR.sup.6 --, --N(R.sup.6)C(.dbd.S)O--, --C(.dbd.NOR.sup.1)--, --S(O).sub.2 N(R.sup.6)--, --N(R.sup.6)S(O).sub.2 --,--N(R.sup.6)C(O)O-- or --OC(O)--;T is H, phthalimidyl, aryl, heterocycloalkyl, heteroaryl, cycloalkyl or bridged cycloalkyl;Q is --SR.sup.6, --N(R.sup.6)(R.sup.7), --OR.sup.6, phenyl, naphthyl or heteroaryl;R.sup.6a, R.sup.7a, R.sup.8a, R.sup.9a, R.sup.6 and R.sup.7 are H, C.sub.1-6 alkyl, C.sub.2 -C.sub.6 hydroxyalkyl, C.sub.1 -C.sub.6 alkoxy-C.sub.1 -C.sub.6 alkyl, phenyl or benzyl; or R.sup.6 and R.sup.7, together with the nitrogen to which they are attached, form a ring;R.sup.

Abstract: Disclosed are compounds of Formula I: ##STR1## or a pharmaceutically acceptable salt or solvate thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula I, methods for inhibiting tumor necrosis factor-.alpha. and methods for treating septic shock, inflammation, or allergic disease.

Abstract: The invention relates to compounds of the formula ##STR1## wherein X, i, j, n, n', A, A', R.sub.2, R.sub.3, and U are as described herein. The compounds of the invention are NK.sub.1 or NK.sub.2 or NK.sub.3 receptor antagonists and as such are useful in the treatment of diseases such as asthma.

Abstract: Disclosed are novel compounds having structural formula (I) ##STR1## or a pharmaceutically acceptable salt thereof, wherein X is hydrogen, halo, --CF.sub.3 or lower alkyl; Y is --(CH.sub.2).sub.n --, wherein n is 0, 1, 2 or 3, --C(O)--, --CH.sub.2 C(O)--, --CH.sub.2 CH.sub.2 C(O)-- or --CH(OH)--; A is --N(R)-- and B is --CH.sub.2 --, or A is --CH.sub.2 -- and B is --N(R)--; R is hydrogen, lower alkyl, lower alkanoyl, --CO.sub.2 R.sup.1, (a) or (b); R.sup.1 is hydrogen, lower alkyl or --CH.sub.2 CCl.sub.3 ; and - - - - represents an optional double bond, with the proviso that the ring containing Y has only one optional double bond. Also disclosed are pharmaceutical compositions comprising these compounds and their use in treating allergy and inflammation.

Abstract: A compound of formula I ##STR1## with R.sup.1 being an alkyl group substituted by one or more substituents and esters thereof at the 2-carboxy group or at the 8-hydroxy group or both; and salts thereof. Compounds I have antibacterial effect. Various intermediates are described. This compound of the formula I, or an ester at the 2-carboxy group or at the 8-hydroxy group or both or a salt thereof is produced by reacting a compound of formula II or of formula IX ##STR2## in which R represents a hydrogen atom or a carboxy protecting group, R.sup.3 represents an activated carboxylic acid group, R.sup.4 represents an alkyl group having 1 to 4 carbon atoms, or a phenyl group which may be unsubstituted or substituted, R.sup.15 represents a phenyl group or an alkyl group having from 1 to 4 carbon atoms, and X represents an oxygen or sulphur with an amine of the formula III R.sup.1 NH.sub.

Abstract: A compound of the formula I ##STR1## in which R.sup.1 represents a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms, the --CONHR.sup.1 group being present at the 3- or 4-position on the phenyl ring, and esters thereof at the 2-carboxyl group and/or at the 8-hydroxy group, have antibacterial and/or .beta.-lactamase inhibiting activity.